Informa
基調セッション

Jochen Salfeld, PhD

標的と治療法:ヒュミラなどの細胞壊死因子 (TNF) アンタゴニストから得られた教訓

AbbVie Bioresearch Center

Tomoyuki Igawa, Ph.D.

抗体改変技術が促す創薬

Chugai Pharmabody Research Pte. Ltd., Singapore

Junichi Koga, Ph.D.

抗体薬物複合体、二重特異性抗体、細胞療法薬、腫瘍溶解性ウイルス療法:第一三共による革新的な治療法の開発の進展とパイプライン

Daiichi Sankyo, Japan

Kouhei Tsumoto, PhD

抗体の親和性を高める方法

The University of Tokyo

08:00 - 09:00 60 mins
登録手続き、コーヒー
09:00 - 09:15 15 mins
Pre-Conference Workshop
ワークショップの議長による開会の挨拶
  • Sai Reddy, PhD - Assistant Professor, Department of Biosystems Science & Engineering, ETH Zurich
  • David Johnson, PhD, MBA - Founder and CEO, GigaGen, Inc.
09:15 - 09:45 30 mins
Pre-Conference Workshop
抗体の発見と改変に向けたゲノミクスと酵母ディスプレイ
  • David Johnson, PhD, MBA - Founder and CEO, GigaGen, Inc.
09:45 - 10:15 30 mins
Info
Pre-Conference Workshop
計算的手法と実験的手法の統合による抗体の設計と改変
  • Karthik Viswanathan, Ph.D. - Director, Research, Visterra, Inc.

Over the last decade there have been significant advances in computational protein design methods, high throughput protein characterization, and availability of antibody repertoire data. Convergence of these methods enable structure-guided design and engineering of antibodies. Here we discuss, through examples, application of computational and experimental methods for lead antibody discovery.

10:15 - 10:45 30 mins
Info
Pre-Conference Workshop
抗体クローンの合理的な選択
  • Hiroki Shirai, PhD - Executive Fellow, Modaility Research Laboratories Astellas Pharma

In silico sequence analysis is useful for the rational selection of developable, manufacturable, and "designable" clones. By using our high-resolution antibody modeling protocol which proved competitive at antibody modeling assessment II, we have recently found that one can identify the clones which are relatively easy for successful optimization. Molecular simulation and informatics approaches revealed such "design-ability" corresponds to structural versatility of CDR-H3.

10:45 - 11:15 30 mins
Pre-Conference Workshop
ネットワーキングブレイク
11:15 - 11:45 30 mins
Info
Pre-Conference Workshop
免疫レパートリーの迅速な機能的照合−次世代の抗体探索法
  • Gabriel Cheung, PhD - Senior Director, BioMedicine Design, Pfizer

Numerous disruptive technologies, from NGS of BCRs to bottom-up serum Ig proteomic, have been developed to study B cell repertoires in the past decade. At Pfizer, we are further pushing the boundary of technologies to enable fast and comprehensive interrogation of functionally relevant, antigen specific B cells from both peripheral and bone marrow compartments through the use of proprietary high-throughput automation, novel single cell technology and deep sequencing.

11:45 - 12:15 30 mins
Info
Pre-Conference Workshop
次世代シーケンシング技術を利用したヒトB細胞受容体の免疫プロファイリング
  • Junho Chung, M.D., Ph.D. - Professor, Seoul National University College of Medicine

Next-generation sequencing (NGS) has allowed a massive increase in capacity to

sequence genomes at relatively low cost and in a short time frame. It has revolutionized

multiple aspects of biological research and is actively being adopted into profiling

human B cell receptor (BCR) repertoires. Several NGS platforms are currently available,

with average read lengths of 75 bp to 8,500 bp and different error rates. Using NGS, we

successfully constructed database of BCR repertoire from human volunteers. Afterwards,

we developed algorithms for analyzing the diversity, enrichment pattern, accumulation

of somatic hyper-mutation in BCR repertoire. Through in silico analysis with machine

learning technology we devised strategies to select clones of interest. Now we are actively

applying this technology for the analysis of BCR repertoire in cancer patients.

12:15 - 12:45 30 mins
Info
Pre-Conference Workshop
ハイスループット機能的スクリーニングによる二重特異性抗体の標的発見
  • Pallavi Bhatta, PhD - Principal Scientist, Functional Screening, UCB

To exploit the true potential to access novel biology with bispecific antibodies, we have developed technology to facilitate unbiased target pair identification and validation through grid screening large numbers of bispecific antibodies in functional human cell assays. Combination of our antibody discovery capabilities, a novel bispecific screening format and high throughput flow cytometry or imaging enables us to screen thousands of bispecific antibodies to hundreds of antigen combinations and identify new target pairs for a defined patient phenotype. The technology and a specific example application from patient phenotyping to new target pair discovery will be described.

12:45 - 12:55 10 mins
Pre-Conference Workshop
ワークショップ終了
13:55 - 14:00 5 mins
Main Conference
議長の挨拶
14:00 - 14:45 45 mins
Info
Main Conference
標的と治療法:ヒュミラなどの細胞壊死因子 (TNF) アンタゴニストから得られた教訓
  • Jochen Salfeld, PhD - Vice President, Global Biologics, AbbVie Bioresearch Center

The presentation will focus on the role of the underlying target biology for developing novel Biologics therapeutics using TNF and TNF antagonists as case study. I will discuss the evolution of Anti-TNF approaches, the history of adalimumab and will start to answer the question how to explain some of the apparent clinical differences between the Anti-TNF agents in clinical use today. In this context the learnings about TNF biology and the mechanism of action of TNF antagonists will be discussed and how those learnings impact the development of novel therapeutics.

14:45 - 15:30 45 mins
Info
Main Conference
抗体改変技術が促す創薬
  • Tomoyuki Igawa, Ph.D. - CEO and Research Head, Chugai Pharmabody Research Pte. Ltd., Singapore

Previously, antibody engineering was mainly applied to improve the properties of a parent antibody by methods such as humanization, affinity maturation, stability engineering and half-life extension. Recent advances in antibody engineering have enabled us to conceive and realize novel antibody drug concepts. This presentation describes how antibody engineering technologies can drive the discovery of innovative antibody drugs.

15:30 - 16:00 30 mins
ネットワーキングブレイク
16:00 - 16:30 30 mins
Main Conference
抗体薬物複合体、二重特異性抗体、細胞療法薬、腫瘍溶解性ウイルス療法:第一三共による革新的な治療法の開発の進展とパイプライン
  • Junichi Koga, PhD - Head of R&D Division, Executive Officer, Daiichi Sankyo
16:30 - 17:00 30 mins
Info
Main Conference
抗体の親和性を高める方法
  • Kouhei Tsumoto, PhD - Professor and Director, The University of Tokyo


Physicochemical approaches deepen our insights into antigen-antibody interactions. Recently, we have investigated how we can rationally improve the affinity of antibodies for the targets. Here I introduce our recent progress on engineering affinity of antibody based on physical biochemical approaches.

18:00 - 19:00 60 mins
Info
ネットワーキングディナー

Network with fellow Antibody Engineering & Therapeutics Asia attendees from around the world by attending this Networking Dinner event at S Tokyo restaurant. Sign up to attend this optional dinner by selecting this dinner option during registration (additional fee required)

08:00 - 09:00

登録手続き、コーヒー

More
Showing of Streams
Showing of Streams
15:30 - 16:00

ネットワーキングブレイク

More
Showing of Streams
18:00 - 19:00
Info

ネットワーキングディナー

Network with fellow Antibody Engineering & Therapeutics Asia attendees from around the world by attending this Networking Dinner event at S Tokyo restaurant. Sign up to attend this optional dinner by selecting this dinner option during registration (additional fee required)

More

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。